Neurotrophic factor intervention restores auditory
function in deafened animals
Takayuki Shinohara*†, Göran Bredberg‡, Mats Ulfendahl*§, Ilmari Pyykkö*¶, N. Petri Olivius*¶, Risto Kaksonen*,
Bo Lindström‡, Richard Altschuler储, and Josef M. Miller*储
*Institute for Hearing and Communication Research and Department of Clinical Neuroscience, Karolinska Institutet, and ¶Department of
Otorhinolaryngology, Karolinska Hospital, SE-171 76 Stockholm, Sweden; †Department of Otolaryngology, Ehime University School of
Medicine, Ehime, 791-0295, Japan; ‡Department of Cochlear Implantation, Karolinska Institutet, Huddinge University Hospital,
SE-141 86 Stockholm, Sweden; and 储Kresge Hearing Research Institute, 1301 E. Ann Street, University of Michigan,
Ann Arbor, MI 48109-0506
Communicated by Jozef J. Zwislocki, Syracuse University, Syracuse, NY, December 17, 2001 (received for review July 27, 2001)
H
earing impairment is the most frequent disability of people
in industrialized countries, affecting more than one in seven
individuals. Most hearing loss is caused by destruction of the
sensory cells within the cochlea of the inner ear. In mammals, the
auditory cells do not regenerate, nor are there currently effective
interventions for their repair. Moreover, in the auditory system,
as in other afferent systems, degeneration of the auditory nerve
occurs secondary to the loss of the inner ear sensory cells (hair
cells), thus aggravating the functional impairment. In the severely and profoundly deaf, the cochlear implant (prosthesis) has
been shown to provide an effective habilitative intervention. The
cochlear prosthesis consists of one or more electrodes inserted
into the fluid space of the inner ear. The implant operates by
directly electrically stimulating the auditory nerve, bypassing
damaged or missing sensory receptor cells. This device now
provides significant speech understanding, with a score for
everyday sentence understanding of about 80% without lip
reading in the majority of patients implanted (so far more than
40,000 worldwide) (1–3). However, the cochlear prosthesis depends on remaining excitable auditory nerve fibers, and their
loss severely compromises the effectiveness of the implant and
the hearing benefits it provides. Studies show a clear relationship
between the total number of viable auditory neurons available for stimulation and the performance of subjects receiving
cochlear implants (4, 5).
The secondary degeneration of the afferent nerve fibers is an
unavoidable consequence of damage to sensory receptor cells.
With the discovery of nerve growth factors by Rita Leviwww.pnas.org兾cgi兾doi兾10.1073兾pnas.032677999
Montalcini and colleagues in the 1950s and recent increased
understanding of the role of neurotrophins as survival factors in
the mature nervous system (6), there have been numerous
attempts to define ways to reduce this degeneration, particularly
in the visual and auditory systems, as well as to reduce neural
degeneration at other sites of the central nervous system (CNS).
In the auditory system, efforts to reduce nerve degeneration
secondary to loss of the sensory cells have an immediate clinical
objective of improving the benefits of auditory neural prostheses
to the deaf patient. It would be of great clinical importance if the
neurotrophins could be shown to effect excitability of the
surviving nerve tissue. This effect has not yet been shown in vivo
in the CNS. This study tests the hypotheses that neurotrophic
factor (NTF) treatment both preserves the auditory nerve after
severe peripheral damage and, more importantly, enhances
functional excitability within the nervous system. Positive findings would be of general significance in the neuroscience field.
Interventions to enhance survival of the auditory nerve and its
cell bodies (spiral ganglion cells, SGCs) have been proposed. It has
been demonstrated that direct cochlear infusion of neurotrophic
factors such as neurotrophin-3, brain-derived neurotrophic factor
(BDNF), and glial-derived neurotrophic factor enhances the survival of SGCs after inner hair cell loss (7–9). Moreover, in vitro
studies indicate that an interaction among factors may synergistically enhance SGC survival (10). Thus, BDNF and ciliary neurotrophic factor (CNTF) were found to be more effective in promoting the survival of neurons in dissociated cell cultures than either
factor individually (11); the combination of BDNF and fibroblast
growth factor 1 was demonstrated to be more effective than either
agent alone in enhancing SGC survival and in inducing regrowth of
their peripheral processes (12).
Although NTFs increase SGC survival after inner hair cell
loss, it has yet to be demonstrated that enhanced survival is
associated with an enhancement of functional capability. An
improvement in auditory system responsiveness will be important if such interventions are to be considered for human
application, i.e., to improve the benefits of the cochlear prosthesis, or in future designs of sensory neuroprostheses. We have
therefore investigated whether the combination of BDNF and
the ciliary neurotrophic factor analogue CNTFAx1 will enhance
not only SGC survival but also the responsiveness of the auditory
system in vivo by using an animal model. The influence of
chronic treatment of the inner ear with the combination of NTFs
on auditory system responsiveness and SGC survival after
deafness was investigated.
Abbreviations: AP, artificial perilymph; eABR, electrically evoked auditory brainstem response; NTF, neurotrophic factor; SGC, spiral ganglion cell; BDNF, brain-derived neurotrophic factor; CNTF, ciliary neurotrophic factor.
§To
whom reprint requests should be addressed. E-mail: mats.ulfendahl@ihk.ki.se.
The publication costs of this article were defrayed in part by page charge payment. This
article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C.
§1734 solely to indicate this fact.
PNAS 兩 February 5, 2002 兩 vol. 99 兩 no. 3 兩 1657–1660
NEUROBIOLOGY
A primary cause of deafness is damage of receptor cells in the inner
ear. Clinically, it has been demonstrated that effective functionality
can be provided by electrical stimulation of the auditory nerve,
thus bypassing damaged receptor cells. However, subsequent to
sensory cell loss there is a secondary degeneration of the afferent
nerve fibers, resulting in reduced effectiveness of such cochlear
prostheses. The effects of neurotrophic factors were tested in a
guinea pig cochlear prosthesis model. After chemical deafening to
mimic the clinical situation, the neurotrophic factors brain-derived
neurotrophic factor and an analogue of ciliary neurotrophic factor
were infused directly into the cochlea of the inner ear for 26 days
by using an osmotic pump system. An electrode introduced into the
cochlea was used to elicit auditory responses just as in patients
implanted with cochlear prostheses. Intervention with brainderived neurotrophic factor and the ciliary neurotrophic factor
analogue not only increased the survival of auditory spiral ganglion neurons, but significantly enhanced the functional responsiveness of the auditory system as measured by using electrically
evoked auditory brainstem responses. This demonstration that
neurotrophin intervention enhances threshold sensitivity within
the auditory system will have great clinical importance for the
treatment of deaf patients with cochlear prostheses. The findings
have direct implications for the enhancement of responsiveness in
deafferented peripheral nerves.
Methods
Study Design. The effect of NTFs on auditory function was tested
in a guinea pig cochlear prosthesis model. To mimic the clinical
situation, all animals were chemically deafened, resulting in
complete sensory cell loss and, as a consequence, progressive
degeneration of the SGCs and their nerve fibers. After the
deafening procedure, NTFs were infused directly to the cochlea
of the inner ear. A platinum–iridium electrode was introduced
into the cochlea and used to elicit auditory responses just as in
patients implanted with cochlear prostheses. Auditory responsiveness was assessed by using electrically evoked auditory
brainstem responses (eABRs).
Surgery and Cochlear Infusion. Pigmented guinea pigs (250–500 g;
n ⫽ 10) were deeply anaesthetized (xylazine 10 mg/kg, i.m.,
ketamine 40 mg/kg, i.m.), and the middle ear was exposed by
means of a postauricular approach. Inner ear infusion was
accomplished by means of an indwelling microcannula–osmotic
pump system (Model 2002, Alza) connected to the cochlea by a
cannula inserted into the basal turn slightly lateral to the round
window, allowing access to the scala tympani (13). Before
implantation, the cannula was preloaded with 4 l of artificial
perilymph (AP) and 24 l of concentrated 10% neomycin
solution; the pump was filled with either AP or BDNF ⫹
CNTFAx1. Because the output of the pump is calibrated at 0.5
l/h, AP was infused into the scala tympani for the first 8 h
followed by the 10% neomycin infusion for 48 h. The cochlea was
then infused for an additional 12 days with the material in the
pump reservoir (i.e., BDNF兾CNTFAx1, or AP). The osmotic
pump was changed on day 15, and the infusion continued until
experimental day 29. In five subjects, deafening (i.e., neomycin
infusion) was followed by cochlear infusion for 26 days with a
combination of BDNF (100 g/ml) and CNTFAx1 (100 ng/ml).
Five animals served as controls and received AP (containing 137
mM NaCl, 2 mM CaCl2, 5 mM KCl, 1 mM MgCl2, 1 mM NaH2PO4,
12 mM NaHCO3, and 11 mM glucose) instead of NTFs for the
same period. Otherwise, the protocol was identical.
All animal procedures were performed in accordance with
national regulations for care and use of animals (Stockholm Northern Animal Care and Use Committee approval no. N154兾98).
Auditory Responses. At the time of pump implantation, a platinum–
iridium ball electrode (Pt–Ir 90%兾10%, 250-m diameter) was
inserted through the round window membrane and placed ⬇1.5
mm into the scala tympani to elicit eABRs. The return wire
(125-m diameter, Pt–Ir) was placed against the occipital bone
beneath the dorsal neck muscles. A percutaneous connector was
cemented to the dorsal skull with carboxylate cement. The eABRs
were recorded in anaesthetized animals in a soundproof room by
using the method described by Hall (14), in which responses to
alternate polarity current pulses are summed, each pair providing
charge balancing. Averages of 2,048 responses, to 50-s computergenerated monophasic current pulses, presented at 50 pulses per
second with an alternating polarity, were recorded between the
vertex screw and a reference electrode inserted s.c. just below the
contralateral ear. A needle inserted at the right lower extremity
served to ground the subject. The eABRs typically demonstrated a
classic waveform, consisting of five positive waves. Thresholds could
be determined from waves I and III in most recordings. However,
as wave I frequently was obscured by the electrical artifact, wave III
(P3) was routinely used for determining the eABR threshold.
Threshold was defined as the lowest stimulus level, in 50-A steps,
that evoked a replicable waveform (typically ⬎0.4 V). The eABRs
were assessed at weekly intervals throughout the treatment period.
The final eABR, followed by the killing of each subject, was
performed on day 31.
1658 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.032677999
Fig. 1. Mean and SD of the eABR thresholds observed in the AP and NTF
treatment groups at different days after the onset of deafness. On day 31, the
thresholds for the AP group ranged from ⬇450 to 650 A, whereas the
thresholds for the NTF group ranged from ⬇150 to 400 A. There was no
overlap between the two treatment groups. The mean eABR thresholds were
significantly different between these groups on days 17, 24, and 31 (P ⫽ 0.019,
0.014, and 0.007, respectively; Student’s t test).
Histology. To determine the survival of SGCs, the animals were
deeply anaesthetized and fixed by cardiac perfusion (3% glutaraldehyde in phosphate buffer). After decalcification in EDTA
and embedding in paraffin, 6-m sections were cut in a paramodiolar plane. Every fourth section was mounted on a glass
slide and stained with toluidine blue. Six sections were randomly
selected from the 10 most mid-modiolar sections for each animal
and used for quantitative analysis of SGCs. The counting was
performed double blind. All neurons meeting size and shape
criteria to be considered type I SGCs within each profile of
Rosenthal’s canal from base to apex of the cochlea were counted.
The outline of the Rosenthal’s canal profile was then traced to
generate a SGC density, expressed as the density of SGC for an
area of 10,000 m2.
Statistics. Statistical assessment of differences in SGC density
and eABR thresholds between the groups was performed by
using ANOVA and the Student’s t test.
Results
eABRs. Immediately after the deafening procedure, there was little
difference between the eABRs evoked in the two groups of
subjects. However, substantial changes occurred during the course
of the treatment. Fig. 1 illustrates the mean and standard deviation
of the threshold of the eABR in A for each treatment group. In
the group treated with AP, eABR thresholds demonstrated a small
but systematic increase throughout the treatment period after the
deafening procedure and electrode implantation. However, in the
deafened subjects treated with BDNF ⫹ CNTFAx1, eABR thresholds showed a systematic decrease throughout the treatment period.
The rate of change in the threshold of the NTF-treated group was
greatest immediately after treatment. Analysis of the slope of
threshold change demonstrated an average slope of ⫺27.3 A/day
for the NTF group. A significant decrease in threshold was observed between days 3 and 17 (paired Student’s t test, P ⫽ 0.009)
and days 3 and 24 (P ⫽ 0.009). For the AP group, the largest change
(threshold elevation) was observed between 17 and 24 days, which
Shinohara et al.
Fig. 2. Representative sections of Rosenthal’s canal in the base of the cochlea
from an AP-treated subject (Upper) and a subject of the NTF-treated subject
(Lower). There is a clear difference in the survival of SGCs in these two subjects.
is consistent with the occurrence of significant SGC degeneration
(15). There were significant differences in mean eABR thresholds
between the two treatment groups on measurement days 17, 24, and
31 (P ⬍ 0.05).
SGC Survival. Intracochlear treatment with the combination of
BDNF and CNTFAx1 resulted in an enhanced survival of SGCs in
the treated cochleae compared with cochleae receiving AP. This
difference is clearly seen in Fig. 2, showing the spiral ganglion
regions in an AP-treated cochlea and in a cochlea that was infused
with NTFs. Across the whole cochlea, for the group receiving AP,
the mean density of SGCs was 12.4 (SEM ⫽ 2.1) whereas for the
group receiving BDNF and CNTFAx1, the mean density (26.7,
SEM ⫽ 5.4) was significantly higher (at P ⬍ 0.05; Fig. 3). There was
a relationship between the recorded eABR thresholds and measured SGC density. The subjects with the greater density of
surviving SGC also demonstrated the lower eABR thresholds.
Discussion
In human patients, cochlear prostheses are usually implanted
more than 6 months after deafness. This period of deafferenShinohara et al.
tation will, at least in animal models, lead to a significant loss of
auditory nerve cells (15, 16). In humans, however, the process is
suggested to be slower (17). Because the benefits of a cochlear
prosthesis have been shown to be strongly correlated to auditory
nerve survival, it is important to implant the profoundly deaf
candidate for a prosthesis as soon as possible after deafness.
Several electrophysiological studies have demonstrated a relationship between the number of SGCs and amplitude growth
function of the eABR (14, 15, 18). Although Hall (14) reported
that the amplitude of the first positive wave was correlated with
the number of SGCs, these previous studies found no relation
between SGC survival and eABR threshold. In this study,
significant differences were observed.
The results show increased sensitivity associated with an increased SGC density in NTF-treated animals. We have demonstrated, in the central nervous system, that a neurotrophin intervention may result in enhanced sensitivity of deafferented neural
tissue in vivo. The increase in the mean SGC density in the
NTF-treated group compared with the AP-treated group is consistent with the observed difference in eABR thresholds. Because
the auditory brainstem responses can be assessed noninvasively in
humans, these results indicate that eABR threshold measurements
may provide a quantitative assay of SGC density in the cochlear
implant candidate. There is, however, an alternative explanation if
one considers the magnitude of the eABR as a measure of
synchronized activity across the SGCs responding to the electrical
stimulus. It is possible that one may obtain a small-magnitude
eABR if the number of SGCs were the same but the neurons did
not respond in a synchronized way. Thus, the eABR may be
indicative of not only the number of responding SGCs, but also the
extent of synchronization of their responses. This study, however,
can not resolve this issue.
The present study supports other recent investigations showing
that neurotrophins enhance SGC survival after deafferentation in
vivo (7–9). More importantly, this investigation demonstrated that
the prevention of loss of SGCs by NTF significantly improves
PNAS 兩 February 5, 2002 兩 vol. 99 兩 no. 3 兩 1659
NEUROBIOLOGY
Fig. 3. The observed mean and SEM of SGC density in AP- and NTF-treated
groups. In the AP group, SGC density ranged from ⬇5,000 to 20,000 cells per
10,000 m2. In the NTF-treated group, survival ranged from 11,000 to 39,000
cells per 10,000 m2. The mean difference was significant. *, P ⬍ 0.05.
hearing sensitivity to electrical stimulation. Clearly there are many
practical hurdles to the safe application of NTF in the inner ear of
humans. However, when safety issues are resolved, this study
supports the clinical utility of NTF as adjunct treatment at the time
of cochlear prosthetic surgery.
We thank Regeneron Pharmaceuticals (Tarrytown, NY) for generously
supplying the neurotrophic factors, Ms. A.-M. Lundberg for technical
assistance, and Dr. L. Järlebark for helpful comments. This work was
supported by grants from the Swedish Research Council, the Swedish
Council for Working Life and Social Research, the Petrus and Augusta
Hedlund Foundation, the Foundation Tysta Skolan, the Åke Wiberg
Foundation, the Swedish Foundation for International Cooperation in
Research and Higher Education, Ångpanneföreningens Stiftelse, and in
part by National Institutes of Health Grant DC03820, the Ruth and Lynn
Townsend Professorship, and the European Union Biotechnology research program (BIO4-CT98-0408).
1. Skinner, M. W., Clark, G. M., Whitford, L. A., Seligman, P. M., Staller, S. J.,
Shipp, D. B., Shallop, J. K., Evringham, C., Menapace, C. M., Arndt, P. L., et
al. (1994) Am. J. Otol. 15 Suppl. 2, 15–27.
2. Kiefer, .J., Muller, J., Pfenningdorff, T., Schön, F., Helms, J., von Illberg, C.,
Baumgartner, W., Gstöttner, W., Ehrenberger, J., Arnold, W., et al. (1996) ORL
Otorhinolaryngol. Relat. Spec. 58, 127–135.
3. Illg, A., von der Haar-Heise, S., Goldring, J. E., Lesinski-Schiedat, A., Battmer,
R. D. & Lenarz, T. (1999) Ann. Otol. Rhinol. Laryngol., Suppl. 177, 93–98.
4. Nadol, J. J., Young, Y. S. & Glynn, R. J. (1989) Ann. Otol. Rhinol. Laryngol.
98, 411–416.
5. Gantz, B. J., Woodworth, G. G., Knutson, J. F., Abbas, P. J. & Tyler, R. S.
(1993) Ann. Otol. Rhinol. Laryngol. 102, 909–916.
6. Mattson, M. P. & Furukawa, K. (1998) Perspect. Dev. Neurobiol. 5, 337–352.
7. Staecker, H., Kopke, R., Malgrange, B., Lefebvre, P. & Van De Water, T. R.
(1996) NeuroReport 7, 889–894.
8. Ernfors, P., Duan, M. L., ElShamy, W. M. & Canlon, B. (1996) Nat. Med. 2,
463–467.
9. Miller, J. M., Chi, D. H., O’Keeffe, L. J., Kruszka, P., Raphael, Y. & Altschuler,
R. A. (1997) Int. J. Dev. Neurosci. 15, 631–643.
10. Hegarty, J. L., Kay, A. R. & Green, S. H. (1997) J. Neurosci. 17,
1959–1970.
11. Hartnick, C. J., Staecker, H., Malgrange, B., Lefebvre, P. P., Liu, W., Moonen,
G. & Van De Water, T. R. (1996) J. Neurobiol. 30, 246–254.
12. Altschuler, R. A., Cho, Y., Ylikoski, J., Pirvola, U., Magal, E. & Miller, J. M.
(1999) Ann. N.Y. Acad. Sci. 884, 305–311.
13. Brown, J. N., Miller, J. M., Altschuler, R. A. & Nuttall, A. L. (1993) Hear. Res.
70, 167–172.
14. Hall, R. D. (1990) Hear. Res. 49, 155–168.
15. Jyung, R. W., Miller, J. M. & Cannon, S. C. (1989) Otolaryngol. Head Neck Surg.
101, 670–682.
16. Leake, P. A. & Hradek, G. T. (1988) Hear. Res. 33, 11–33.
17. Otte, J., Schuknecht, H. F. & Kerr, A. G. (1978) Laryngoscope 88,
1231–1246.
18. Smith, L. & Simmons, F. B. (1983) Ann. Otol. Rhinol. Laryngol. 92, 19–23.
1660 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.032677999
Shinohara et al.